New, long-term data for VOYDEYA™ as add-on to ULTOMIRIS® or SOLIRIS® will show low rate of breakthrough hemolysis events and sustained improvements in quality-of-life measures in PNH with ...
Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Complement C5 Inhibitors & C5 Receptor Antagonists" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence ...
Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The ...
An AstraZeneca drug acquired in a $930 million deal has received FDA approval as a treatment for a rare blood disorder. In this disease, paroxysmal nocturnal hemoglobinuria (PNH), a part of the immune ...
EXTON, PA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights has released its first annual chart audit study in hematology, PatientChart Dynamix™ : Paroxysmal Nocturnal Hemoglobinuria (PNH) ...
Findings showed treatment with Ultomiris resulted in a statistically significant and clinically meaningful reduction in the risk of relapse compared with the external placebo arm. The Food and Drug ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in hematology at the 66 th American Society ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results